Protocol Ledger

NCT05907122 · Phase III · COMPLETED

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Interventional Phase III clinical trial protocol NCT05907122 sponsored by Amgen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-26 Enrollment: 256 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05907122
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)256 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05907122
Protocol FieldVerified Registry Value
NCT IdentifierNCT05907122
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment256 participants (ACTUAL)
Registered Start Date2023-07-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05907122
Hospital Research SiteLocationSite Profile
Azienda Ospedaliera Universitaria Federico IINaples, ItalyOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI